PubMed · 10925698
[Pharmacokinetically guided dose-escalation (PGDE) strategy].
Abstract
When a phase I clinical trial is conducted, the dose escalation strategy is most critical. According to the results of preclinical trials, a rapid and safe dose escalation is necessary. In this regard, a pharmacokinetically guided dose-escalation (PGDE) strategy has been developed. An accelerated dose escalation is conducted by PGDE until reaching 40% target AUC. To determine the MTD of target anti-cancer agents, PGDE appears to be useful.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
T Saeki. 2000. [Pharmacokinetically guided dose-escalation (PGDE) strategy].. https://pubmed.ncbi.nlm.nih.gov/10925698/
Cite the original work for its findings. Save a collection to share your selection of sources.